Get started
Work

A PTPmu Biomarker is Associated with Increased Survival in Gliomas

Year: 2019
Type: article
Study design: Observational Study
Abstract: An integrated approach has been adopted by the World Health Organization (WHO) for diagnosing brain tumors. This approach relies on the molecular characterization of biopsied tissue in conjunction with standard histology. Diffuse gliomas (grade II to grade IV malignant brain tumors) have a wide range in overall survival, from months for the worst cases of glioblastoma (GBM) to years for lower grade astrocytic and oligodendroglial tumors. We previously identified a change in the cell adhesion molecule PTPmu in brain tumors that results in the generation of proteolytic fragments. We developed agents to detect this cell surface-associated biomarker of the tumor microenvironment. In the current study, we evaluated the PTPmu biomarker in tissue microarrays and individual tumor samples of adolescent and young adult (n = 25) and adult (n = 69) glioma populations using a fluorescent histochemical reagent, SBK4-TR, that recognizes the PTPmu biomarker. We correlated staining with clinical data and found that high levels of the PTPmu biomarker correlate with increased survival of glioma patients, including those with GBM. Patients with high PTPmu live for 48 months on average, whereas PTPmu low patients live only 22 months. PTPmu high staining indicates a doubling of patient survival. Use of the agent to detect the PTPmu biomarker would allow differentiation of glioma patients with distinct survival outcomes and would complement current molecular approaches used in glioma prognosis.
DOI: 10.3390/ijms20102372
Authors: Mette L. Johansen, Jason Vincent, Haley Gittleman, Sonya E. L. Craig, Marta Couce, Andrew E. Sloan, Jill S. Barnholtz-Sloan, Susann M. Brady-Kalnay
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,824
Funders: Alex's Lemonade Stand Foundation for Childhood Cancer, Char and Chuck Fowler Family Foundation, National Institutes of Health, National Eye Institute, National Cancer Institute, National Institute of Neurological Disorders and Stroke
Awards: Hamamatsu Nanozoomer S60 Digital Whole Slide Scanner, A Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain Tumors, G2737633914, (PQC5) Detecting small clusters of tumor cells with a PTPmu probe, PTP mu Supresses Brain Tumor Cell Migration and Dispersal, Detecting invading glioma cells through in vivo molecular imaging of the cell sur, Case Comprehensive Cancer Center Support Grant, CWRU NEI Vision Center Core Grant
OpenAlex ID: W2945859424
FWCI: 0.412
Cites: 38
Cited by: 5
Related to: 10